down arrow

Poseida Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US73730P1084
USD
9.50
-0.06 (-0.63%)

Jan 10

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

2.329.67
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Sep 2024)

FII

2.38%

Held by 56 FIIs

DII

68.53%

Held by 35 DIIs

Promoter

0.00%

How big is Poseida Therapeutics, Inc.?

22-Jun-2025

As of Jan 10, Poseida Therapeutics, Inc. has a market capitalization of 925.92 million and reported net sales of 150.86 million with a net profit of -60.76 million over the latest four quarters. Shareholder's funds are 103.70 million, and total assets amount to 273.88 million.

As of Jan 10, Poseida Therapeutics, Inc. has a market capitalization of 925.92 million, categorizing it as a Micro Cap company.<BR><BR>As of Jan 10, the sum of net sales for the latest four quarters is 150.86 million, while the sum of net profit for the same period is -60.76 million.<BR><BR>As of Dec 23, the shareholder's funds are reported at 103.70 million, and total assets amount to 273.88 million.

Read More

What does Poseida Therapeutics, Inc. do?

22-Jun-2025

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a diverse range of product candidates. As of September 2024, it reported net sales of $72 million and a net profit of $20 million, with a market cap of approximately $926 million.

Overview:<BR>Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company in the biotechnology industry, focusing on the development of a broad portfolio of product candidates.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 72 Million (Quarterly Results - Sep 2024)<BR>- Most recent Net Profit: 20 Million (Quarterly Results - Sep 2024)<BR>- Market cap: USD 925.92 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 92.45%<BR>- Debt Equity: -1.90<BR>- Return on Equity: -69.67%<BR>- Price to Book: 10.62<BR><BR>Contact Details:<BR>- Address: 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA: 92121<BR>- Tel: 1 858 7793100<BR>- Fax: 1 302 6365454<BR>- Website: https://poseida.com/

Read More

Should I buy, sell or hold Poseida Therapeutics, Inc.?

22-Jun-2025

Who are in the management team of Poseida Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Poseida Therapeutics, Inc. includes Dr. Eric Ostertag (CEO), Mr. Mark Gergen (CBO/CFO), Dr. Catherine Mackey (Lead Independent Director), and several independent directors: Mr. Luke Corning, Dr. David Hirsch, Ms. Marcea Lloyd, and Mr. Sean Murphy. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Poseida Therapeutics, Inc. includes the following individuals:<BR><BR>- Dr. Eric Ostertag, who serves as the Chief Executive Officer and Director.<BR>- Mr. Mark Gergen, who holds the positions of Chief Business Officer, Chief Financial Officer, and Director.<BR>- Dr. Catherine Mackey, who is the Lead Independent Director.<BR>- Mr. Luke Corning, who is a Director.<BR>- Dr. David Hirsch, who serves as an Independent Director.<BR>- Ms. Marcea Lloyd, who is also an Independent Director.<BR>- Mr. Sean Murphy, who is another Independent Director. <BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a growth in Net Profit of NAN%, the company declared Outstanding results in Sep 24

  • The company has declared positive results for the last 3 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD -15.02 MM
  • DEBT-EQUITY RATIO (HY) Lowest at -169.85 %
  • RAW MATERIAL COST(Y) Fallen by -16.31% (YoY)
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 926 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

92.45%

stock-summary
Debt Equity

-1.90

stock-summary
Return on Equity

-69.67%

stock-summary
Price to Book

10.62

Revenue and Profits:
Net Sales:
72 Million
(Quarterly Results - Sep 2024)
Net Profit:
20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
257.14%
0%
257.14%
6 Months
218.79%
0%
218.79%
1 Year
199.68%
0%
199.68%
2 Years
42.0%
0%
42.0%
3 Years
48.67%
0%
48.67%
4 Years
0%
0%
0.0%
5 Years
520.92%
0%
520.92%

Poseida Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
173.08%
EBIT Growth (5y)
-3.35%
EBIT to Interest (avg)
-19.90
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.90
Sales to Capital Employed (avg)
0.56
Tax Ratio
0.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
64.23%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.62
EV to EBIT
-12.16
EV to EBITDA
-13.33
EV to Capital Employed
-9.66
EV to Sales
5.04
PEG Ratio
NA
Dividend Yield
92.45%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-69.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 31 Schemes (29.08%)

Foreign Institutions

Held by 56 Foreign Institutions (2.38%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 175.77% vs -7.47% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2024 is 164.33% vs -29.22% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "71.70",
          "val2": "26.00",
          "chgp": "175.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "21.00",
          "val2": "-30.40",
          "chgp": "169.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "2.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "20.20",
          "val2": "-31.40",
          "chgp": "164.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "275.20%",
          "val2": "-1,222.70%",
          "chgp": "149.79%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is -50.42% vs 318.27% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is -92.81% vs 48.80% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "64.70",
          "val2": "130.50",
          "chgp": "-50.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-190.50",
          "val2": "-107.60",
          "chgp": "-77.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "8.70",
          "val2": "6.40",
          "chgp": "35.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-123.40",
          "val2": "-64.00",
          "chgp": "-92.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,030.80%",
          "val2": "-864.00%",
          "chgp": "-216.68%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - QoQstock-summary
Sep'24
Jun'24
Change(%)
Net Sales
71.70
26.00
175.77%
Operating Profit (PBDIT) excl Other Income
21.00
-30.40
169.08%
Interest
2.30
2.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
20.20
-31.40
164.33%
Operating Profit Margin (Excl OI)
275.20%
-1,222.70%
149.79%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2024 is 175.77% vs -7.47% in Jun 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2024 is 164.33% vs -29.22% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
64.70
130.50
-50.42%
Operating Profit (PBDIT) excl Other Income
-190.50
-107.60
-77.04%
Interest
8.70
6.40
35.94%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-123.40
-64.00
-92.81%
Operating Profit Margin (Excl OI)
-3,030.80%
-864.00%
-216.68%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is -50.42% vs 318.27% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is -92.81% vs 48.80% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Poseida Therapeutics, Inc. stock-summary
stock-summary
Poseida Therapeutics, Inc.
Biotechnology
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac deoxyribonucleic acid (DNA) Modification System, Cas-CLOVER site-specific gene editing system and nanoparticle- and adeno-associated virus (AAV)-based gene delivery technologies. The Company’s product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101.
Company Coordinates stock-summary
Company Details
9390 TOWNE CENTRE DRIVE, SUITE 200 , SAN DIEGO CA : 92121
stock-summary
Tel: 1 858 77931001 858 7793100
stock-summary
https://poseida.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."